英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
liquidy查看　liquidy　在百度字典中的解释百度英翻中〔查看〕
liquidy查看　liquidy　在Google字典中的解释Google英翻中〔查看〕
liquidy查看　liquidy　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Targeting TRPV6 CXCR4 complexes prevents castration-resistant . . .
    Bone metastasis most commonly occurs in castration-resistant prostate cancer (CRPC) The TRPV6 calcium channel is absent in healthy prostate tissue, but its expression increases considerably
  • Recent Advances in the Treatment of Metastatic Castration . . .
    Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | Around the Practice | CancerNetwork is home to the journal Oncology provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers
  • Metastatic castration-resistant prostate cancer (mCRPC)
    Overview Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that has spread away from the prostate and no longer responds to hormone therapy treatments Hormone therapy for prostate cancer, also called androgen deprivation therapy (ADT), lowers the levels of the hormone testosterone in the body Prostate cancer cells typically use testosterone to help them grow
  • Recent Advances in Androgen Receptor Pathway Inhibitors for . . .
    Prostate cancer (PCa) is the second most common cancer in men, and it is frequently diagnosed at an advanced stage of the disease Androgen Deprivation Therapy (ADT) has traditionally represented the backbone of therapy for high-risk, recurrent, and metastatic disease; however, in the last ten years a new group of molecules known as androgen receptor pathway inhibitors (ARPIs) have been
  • Efficacy and safety of treatments for metastatic castration . . .
    Background Androgen deprivation therapy (ADT) has been the foundational treatment for management of patients with metastatic prostate cancer since the pioneering efforts of Huggins and Hodges [1]
  • U. S. FDA approves AKEEGA® as the first precision therapy for . . .
    Metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC), refers to prostate cancer that has spread to other parts of the body but still responds to hormone therapy (androgen deprivation therapy) 3 While the treatment landscape has advanced in recent years, almost all patients
  • Assessment of Androgen Receptor Splice Variant-7 as a . . .
    The treatment landscape for advanced prostate cancer is rapidly changing with the demonstration that AR-targeting therapies improve the overall survival for patients with advanced CSPC, raising the question of whether AR-V7 may serve as a predictive biomarker earlier in the prostate cancer paradigm (3)
  • TYPES OF TREATMENTS FOR METASTATIC PROSTATE CANCER
    ADVANCED PROSTATE CANCER Prostate cancer that has spread beyond the prostate to other parts of a man’s body is considered advanced prostate can-cer In some cases, this might mean it has spread to nearby lymph glands or the seminal vesicles and is referred to as Stage III prostate cancer Additionally, the progression from castration sensitive to castration resistant may also be considered
  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1





中文字典-英文字典  2005-2009